Best-value medicines
The Medicines Management Programme has identified best-value medicines in the following areas:
- Best-value biological medicines: adalimumab + etanercept
- Glatiramer acetate
- Long-acting granulocyte-colony stimulating factors
- Teriparatide
BVB/BVM Processes 2024
Information in relation to potential best-value biological (BVB) medicine and best-value medicine (BVM) processes for 2024.